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Dear Editor,
A previously healthy 5-year-old Portuguese boy presented
to our Emergency Department (ED) with a history of
4 days of high fever and painful abdomen. He had been
living in Mozambique (Matola) for the last year and didn’t
held malaria prophylaxis. At the time of admission, he
was febrile and jaundiced, and a splenomegaly was no-
ticed on physical examination. Initial laboratory data
showed leucopenia, thrombocytopenia, high liver enzymes,
direct hyperbilirubinemia, and elevated C-reactive protein.
The diagnosis of malaria was confirmed by the presence
of Plasmodium falciparum trophozoites in thin and thick
blood films and by positive Plasmodium antigenemia.
Despite a parasitemia of <1 %, he was admitted and
treated with IV quinine and clindamycin with diagnosis
of severe malaria according to WHO criteria (Table 1). On
the following days, his clinical condition deteriorated,
presenting with high fever, hypotension, mucosal bleeding,
pleural effusion, and ascites. Laboratory workout revealed
disseminated intravascular coagulation, pancytopenia, cho-
lestatic hepatitis, hypoalbuminemia, as well as
elevated ferritin (5,890 ng/mL) and soluble CD25 (sIL2R
=4,352 U/mL). Other co-infections were excluded
(Table 1).
Despite the diagnosis of Falciparum malaria-associated
hemophagocytic lymphohistiocytosis (HLH), he did not re-
ceive HLH-directed therapy and was treated with
antimalaric drugs and supportive measures: packed red cells,
platelets, fresh frozen plasma, cryoprecipitate, purified con-
centrate of fibrinogen, as well as inotropic support with
dopamine (day 2 - 4). His clinical and laboratory condition
slowly improved (Table 1). He was discharged home 12 days
after being hospitalized.
A hereditary cause for HLH was not investigated due the
prompt improvement without HLH-targeted therapy.
HLH is a potentially fatal hyperinflammatory condition
caused by a highly stimulated but ineffective immune re-
sponse [1]. It has been described as a familial disorder (due
to defects in Nk citotoxicity) and as a sporadic one [2]. The
latter has been associated with infections, malignancies, or
rheumatologic disorders [3].
Infection-associated HLH can be triggered by virus,
bacteria, fungi, or protozoa [1–4], but P. falciparum has
rarely been reported as a cause of HLH [5–7], especial-
ly in children [10].
A deranged immune response is the cause of HLH, and
the associated cytokine storm is responsible for the major-
ity of the clinical and laboratory abnormalities [1–4]. The
clinical diagnosis is established fulfilling five of the eight
HLH-2004 criteria [1]. Noteworthy are the facts that
hemophagocytosis is not required for establishing the di-
agnosis, that ferritin levels above 10,000 ng/mL are highly
specific for HLH and that very high levels of sIL2Rα are
almost never seen outside HLH [3].
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The authors believe that despite being rarely described,
HLH-associated malaria should be suspected in patients with
severemalaria and unexpectedmultiorgan failure. Experimen-
tal studies have demonstrated that several soluble exoantigens
of P. falciparum induce inappropriate macrophage activation
and a Th1-stimulated hypercytokinemia with excessive pro-
duction of the TNF-α and INF-γ [8], which are some of the
major cytokines responsible for HLH. This has also been well
described with other infectious agents, such as EBV [9].
Most cases of malaria-induced HLH reported in literature
have responded completely to antimalarial therapy alone
[5–7], as observed in our case. Nevertheless, like in EBV-
associated HLH [10], in the rare cases where there is progres-
sion of HLH despite appropriate antimalarial therapy, a step-
wise approach can probably be applied, in order to allow
disease control without jeopardizing the infection control.
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Laboratory evaluation Day 1 Day 2–3 Day 12
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WBC (×109/L) 3.8 3.8 9.6
ANC (×109/L) 1.99 0.94 4.22
Platelet count (×109/L) 21 9 502
PT (s)/INR/APTT (s) 11.1/0.97/37 16.6/1.45/53.3 10.8/0.95/30.8
Fibrinogen (g/L) – 0.6 1.5
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AST/ALT/LDH (U/L) 147/84/1063 139/76/1411 53/53/510
GGT/ ALP (U/L) 281/605 190/626 141/622
T-Bil/D-Bil (mg/dL) 10.53/6.09 10.91/6.71 2.33/0.87
Triglycerides (mg/dL) 91 306 197
Albumin (g/L) – 21 36
BUN/creatinine (mg/dL) 34/0.46 51/0.62 12/0.20
Na (mEq/L) 129 135 139
Ferritin (ng/mL) – 5890 734
sCD25 (U/mL) – 4352 –
Plasmodium falciparum Positive antigenemia
Trophozoites on
peripheral blood smear
Parasite density 0 %
Positive antigenemia
Trophozoites on
peripheral blood smear
Negative
antigenemia
EBV, CMVand PVB19 serology,
blood cultures, O&P test
Negative
Normal range—hemoglobin, 11.5–13.5 g/dL; WBC, 5–15×109 /L; ANC, 1.5–8×109 /L; platelet count, 200–450×109 /L; PT, 10.1–12.1 s; INR, 0.91–
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U/L; ALP, 86–362 U/L; T-Bil, 0.3–1.2 mg/dL;D-Bil, 0–0.2 mg/dL; triglycerides, <150 mg/dL; albumin, 35–52 g/L; BUN, 10.8–38.4 mg/dL; creatinine,
0.16–0.39 mg/dL; Na, 136–145 mEq/L; ferritin, 24–336 ng/mL; sCD25, <1,000 U/mL. Bold numbers - abnormal values
WBC white blood cell, ANC absolute neutrophil count, PT prothrombin time, INR international normalized ratio, APTT activated partial thromboplastin
time, CRP C-reactive protein, AST aspartate aminotransferase, ALT alanine aminotransferase, LDH lactate dehydrogenase, GGT gamma-glutamyl
transferase, ALP alkaline phosphatase, T-Bil total bilirubin, D-Bil direct bilirubin, BUN blood urea nitrogen, Na sodium, sCD25 soluble CD25, EBV
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